Multiple myeloma (MM) is a plasma cell proliferative disorder that accounts for 10% of all malignant hematologic neoplasms. The American Cancer Society estimates that 16,570 new cases of MM will be diagnosed in the United States in 2006, and that 11,310 people will die from it. In recent years the approach to treatment has changed substantially, and along with it, the prognosis is improving. The plethora of agents newly available, and that will become available shortly, will dramatically reshape MM therapy. This educational activity is designed to improve the understanding of MM and will provide an overview of standard therapies as well as promising therapies in the pipeline. In addition, this activity will examine strategies of sequential therapies, combination therapies, stem cell transplantation, radiotherapy, and supportive care to improve both patient survival and quality of life.